Anavex Life Sciences Corp (OTCMKTS:AVXL) announced that it had received the approval for its Phase 2a Alzheimer trial from Ethics Committee in Australia. As per the reports, it was requested by many patients and their caregivers.
With the help of the trial extension, those participants who have completed 52 weeks in PART B, can roll over into a fresh one and keep on taking ANAVEX 2-73 for another 104 weeks without any hassle. Through this, they can be assured of additional efficacy and safety data. This trial isn’t connected to company’s Phase 2/3 Double-blinded, placebo-controlled research study of ANAVEX 2-73 in Alzheimer’s.
Insights of Matter
The senior management team of the company is delighted to make this announcement and hopes that it will further motivate the company to work towards developing a treatment that can get rid of Alzheimer’s completely. Among many others who have vouched for this treatment, Stephen Macfarlane’s name comes on top of the list. He’s the Principal Investigator of this study and works as the Director – Aged Psychiatry, Alfred Health.
In Macfarlane’s opinion, the company’s receiving continuous positive feedback about ANAVEX 2-73. In addition to functional and cognitive benefits, it has also helped with an overall reduction in agitation and improvement in mood. If research team is allowed to spend more time working on ANAVEX 2-73, it can unearth many other hidden aspects, which can play a critical role in overall patient health cycle.
Anavex is planning to present the dose-response analysis data from ANAVEX 2-73 PART A’s Phase 2a Alzheimer’s trial at the 14th International Symposium on Advances in Alzheimer Therapy. As per the reports, it will be presented by none other than Christopher U. Missling, Ph.D., CEO & President, Anavex. Investors willing to learn more about ANAVEX 2-73 can grab the information from the official website of Anavex.
